Log in

OTCMKTS:XCUR - Exicure Stock Price, Forecast & News

$2.89
+0.05 (+1.76 %)
(As of 12/9/2019 01:00 AM ET)
Today's Range
$2.79
Now: $2.89
$2.97
50-Day Range
$2.45
MA: $2.71
$3.38
52-Week Range
$1.62
Now: $2.89
$4.10
Volume117,260 shs
Average Volume112,334 shs
Market Capitalization$219.63 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Exicure, Inc. engages in the provision of clinical stage biotechnology company. It offers 3-dimensional, spherical nucleic acid architecture unlocks the potential of nucleic acid therapeutics. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:XCUR
CUSIPN/A
Phone(847) 673-1700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees27
Market Cap$219.63 million
Next Earnings DateN/A
OptionableNot Optionable

Receive XCUR News and Ratings via Email

Sign-up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter.


Exicure (OTCMKTS:XCUR) Frequently Asked Questions

What is Exicure's stock symbol?

Exicure trades on the OTCMKTS under the ticker symbol "XCUR."

How were Exicure's earnings last quarter?

Exicure Inc (OTCMKTS:XCUR) issued its earnings results on Thursday, November, 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.01. The company had revenue of $0.53 million for the quarter. View Exicure's Earnings History.

What price target have analysts set for XCUR?

3 Wall Street analysts have issued 12-month price targets for Exicure's stock. Their forecasts range from $5.00 to $9.00. On average, they expect Exicure's share price to reach $7.33 in the next year. This suggests a possible upside of 153.7% from the stock's current price. View Analyst Price Targets for Exicure.

What is the consensus analysts' recommendation for Exicure?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exicure in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exicure.

Has Exicure been receiving favorable news coverage?

News coverage about XCUR stock has trended very negative on Monday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Exicure earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Exicure.

Who are some of Exicure's key competitors?

What other stocks do shareholders of Exicure own?

Who are Exicure's key executives?

Exicure's management team includes the folowing people:
  • David A. Giljohann, Chief Executive Officer & Director
  • Matthias Schroff, Chief Operating Officer
  • David S. Snyder, Chief Financial Officer
  • Jocelyn Trokenheim, Vice President & Head-Business Developemnt

Who are Exicure's major shareholders?

Exicure's stock is owned by a number of of retail and institutional investors. Top institutional investors include Granite Point Capital Management L.P. (0.89%), Emerald Mutual Fund Advisers Trust (0.66%) and Neville Rodie & Shaw Inc. (0.02%). Company insiders that own Exicure stock include Chad A Mirkin, David A Giljohann and David R Walt. View Institutional Ownership Trends for Exicure.

Which institutional investors are buying Exicure stock?

XCUR stock was acquired by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Emerald Mutual Fund Advisers Trust and Neville Rodie & Shaw Inc.. Company insiders that have bought Exicure stock in the last two years include Chad A Mirkin, David A Giljohann and David R Walt. View Insider Buying and Selling for Exicure.

How do I buy shares of Exicure?

Shares of XCUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Exicure's stock price today?

One share of XCUR stock can currently be purchased for approximately $2.89.

How big of a company is Exicure?

Exicure has a market capitalization of $219.63 million. Exicure employs 27 workers across the globe.View Additional Information About Exicure.

What is Exicure's official website?

The official website for Exicure is http://www.exicuretx.com/.

How can I contact Exicure?

The company can be reached via phone at (847) 673-1700.


MarketBeat Community Rating for Exicure (OTCMKTS XCUR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  43
MarketBeat's community ratings are surveys of what our community members think about Exicure and other stocks. Vote "Outperform" if you believe XCUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XCUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Featured Article: Cost of Capital Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel